Pre‐emptive antifungal therapy vs empirical antifungal therapy
Proportion of antifungal agent use (other than prophylactic use) · people with cancer who have febrile neutropenia
It is very uncertain whether pre‐emptive antifungal therapy changes proportion of antifungal agent use (other than prophylactic use) compared with empirical antifungal therapy (very low certainty).
1 finding from 1 review
- Pre‐emptive antifungal therapy versus empirical antifungal therapy for febrile neutropenia in people with cancer 2022 · Cochrane Headline outcomes onlyRR 0.71 [0.47, 1.05]7 studies · 1480 participantsVery low